TELA Bio, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by TELA Bio, Inc., a Delaware corporation, with the earliest event reported on January 1, 2022. The company is an emerging growth company listed on the Nasdaq Global Market under the symbol "TELA".
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and personnel changes rather than financial performance.
Material Changes
The primary material change disclosed is the appointment of a new senior executive officer:
- Appointment: Megan Smeykal was appointed as Chief Accounting Officer and principal accounting officer, effective January 1, 2022.
- Background: Ms. Smeykal joined the company in December 2019 as Vice President of Financial Reporting and was promoted to Vice President – Corporate Controller in May 2021.
- Experience: She previously served at Nutrisystem, Inc. (2006–2019) and Arthur Andersen LLP (1997–2002). She holds a CPA license in Pennsylvania.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on financial performance, or discussion of risks and contingencies. The report confirms there are no undisclosed arrangements or family relationships regarding Ms. Smeykal's appointment.
Investor Verification Checklist
- Verify the effective date of Megan Smeykal's appointment as Chief Accounting Officer (January 1, 2022).
- Confirm the absence of any compensatory arrangements or understandings related to this appointment.
- Note that this filing does not contain updated financial results; refer to the most recent 10-K or 10-Q for financial data.